1) 「中央社会保険医療協議会における費用対効果評価の分析ガイドライン」 (厚生労働科学研究費補助金「医療経済評価の政策応用に向けた評価手法およびデータの標準化と評価のしくみの構築に関する研究」班) (http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000104722.pdf), 2015
2) Eddy DM, et al ; ISPOR-SMDM Modeling Good Research Practices Task Force : Model transparency and validation : a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Medical Decision Making, 32 : 733-743, 2012
3) Tanaka S, et al ; for the Japan Diabetes Complications Study Group ; the Japanese Elderly Diabetes Intervention Trial Group : Predicting Macro- and Microvascular Complications in Type 2 Diabetes : The Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care, 36 : 1193-1199, 2013
4) Hayes AJ, et al : UKPDS outcomes model 2 : a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study : UKPDS 82. Diabetologia, 56 : 1925-1933, 2013
5) Ahmad Kiadaliri A, et al : Towards renewed health economic simulation of type 2 diabetes : risk equations for first and second cardiovascular events from Swedish register data. PLoS One, 8 : e62650, 2013
6) CDC Diabetes Cost-effectiveness Group : Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA, 287 : 2542-2551, 2002
7) Palmer AJ, et al : The CORE Diabetes Model : Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion, 20 Suppl 1 : S5-26, 2004